Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Junshi Bioscience to Raise $414 Million in Hong Kong IPO

publication date: Dec 11, 2018

Shanghai Junshi Bioscience plans to raise up to $414 million in a Hong Kong IPO that will be priced later this week and begin trading on December 24. The IPO values Junshi at $1.9 billion. Seven cornerstone investors have agreed to buy $242 million of the offering. Founded in 2012, Junshi is developing immunoncology candidates and other biologics. It claims to be the first China company to file an NDA for an anti-PD-1 candidate and the first company to be approved for China tests of anti-PCSK9 and anti-BLyS mAbs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital